Targeted therapies in advanced differentiated thyroid cancer

Related Experiment Video

Updated: Apr 8, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K

Raquel M Carneiro1, Benedito A Carneiro2, Mark Agulnik3

  • 1Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, United States; Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine, Northwestern University, United States; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, United States.

Cancer Treatment Reviews
|June 25, 2015
PubMed

Insights

Rising differentiated thyroid cancer incidence necessitates new treatments. Targeted therapies like sorafenib and lenvatinib offer options for advanced disease, but further research is crucial for personalized medicine.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Differentiated thyroid cancer is a common endocrine malignancy with increasing incidence.
  • A subset of patients develops aggressive, treatment-refractory disease.
  • Limited therapeutic options existed for advanced, refractory thyroid cancer previously.

Purpose of the Study:

  • To review the development and application of novel targeted therapies for advanced differentiated thyroid cancer.
  • To highlight the impact of multikinase inhibitors in managing refractory thyroid cancer.
  • To emphasize the need for continued research in personalized thyroid cancer treatment.

Main Methods:

  • Review of recent advancements in targeted therapy for differentiated thyroid cancer.
  • Analysis of the role of small-molecule multikinase inhibitors (sorafenib, lenvatinib).
  • Discussion of current limitations and future research directions.

Main Results:

  • Sorafenib and lenvatinib are approved for radioactive iodine-refractory advanced differentiated thyroid cancer.
  • These targeted therapies represent a significant advancement in treating advanced thyroid cancer.
  • Despite progress, current therapies have limitations requiring further investigation.

Conclusions:

  • Targeted therapies have improved outcomes for advanced differentiated thyroid cancer.
  • Further research is essential to overcome existing limitations and develop personalized treatments.
  • The ultimate goal is to provide safe, effective, and individualized therapy for all advanced thyroid cancer patients.
Keywords:
Differentiated thyroid cancerFollicular thyroid carcinomaTargeted therapyThyroid cancerTyrosine kinase inhibitors

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
113